Varenicline for Tobacco Dependence

Publisher Website
Google Scholar
Abstract
A 57-year-old man presents to his primary care provider because he would like to quit smoking. A trial of varenicline, a partial agonist of the nicotinic acetylcholine receptor that has been shown to increase rates of smoking abstinence as compared with placebo, is recommended. In light of reports of neuropsychiatric side effects, including suicidal behavior, patients treated with varenicline should be closely monitored for behavioral symptoms.

This publication has 31 references indexed in Scilit: